Medtech

Tell Me Why: The 10 Reasons We Invested in ONE

Next Investors Mar 19, 2021

Last Friday we announced our 2021 Tech Pick of the Year, Oneview Healthcare plc (ASX: ONE) - a healthcare technology company that enables ‘virtual care’ at the bedside for hospital patients. We promised that we would provide further analysis on why we have made such a large, long term investment and called ONE our 2021 Tech Pick of the Year…

Oneview’s MedTech combats COVID-19 and keeps everyone safe

Finfeed Archived Jul 31, 2020

A deep re-imagining of how healthcare and patient care is delivered. This is being facilitated by Oneview Healthcare (ASX: ONE), an ASX-listed health-tech provider, which this year launched a cloud-based solution to help healthcare systems manage hospitalised patients during and after COVID-19.

Respiri Limited signs joint development agreement with Phenix Health, surges 50%

Finfeed Archived Apr 14, 2020

Respiri Limited (ASX:RSH), an eHealth SaaS company supporting respiratory health management, signs a joint development venture agreement with Phenix Health Pty Ltd

Non-elective treatment profile provides Avita Medical with income stability

Finfeed Archived Apr 08, 2020

AVITA Medical Limited (ASX: AVH) is a med-tech stock worth targeting outside the blue chips such as ResMed, CSL and Ramsay Health Care.

Investors flock to Lifespot as a telehealth play

Finfeed Archived Mar 25, 2020

Lifespot Health Limited (ASX: LSH) Bodytel® System already has the capability to track blood sugar, ECG, blood pressure and weight via the existing Bluetooth connected devices.

OncoSil granted FDA Breakthrough Device Designation

Finfeed Archived Mar 18, 2020

OncoSil Medical Ltd’s (ASX: OSL) OncoSil™ device has reached a significant milestone, receiving Breakthrough Device Designation by the US FDA for the treatment of unresectable locally advanced pancreatic cancer.

OncoSil on verge of CE Mark approval

Finfeed Archived Feb 27, 2020

The coming 12 months is shaping up as a watershed stage in the history of Oncosil Medical Ltd (ASX:OSL) as it flags the finalisation of commercialisation plans for its OncoSil™ device ahead of CE marking early in 2020.

ASX MedTech Junior Displays Promise for Pancreatic Cancer Patients

Next Investors Archived Jan 30, 2020

OncoSil Medical (ASX: OSL) has developed a first-in-class, truly innovative device that treats unresectable locally advanced pancreatic cancer — that is, tumours that can’t be surgically removed.

HeraBEAT users could be in line for full refunds on the cost of the product

Finfeed Archived Dec 04, 2019

Medical technology company, HeraMED Limited (ASX:HMD) is pursuing verification around the potential for its HeraBEAT and HeraCARE solutions to be reimbursed under the US reimbursement code system.

Page 1 of 4 next >